Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib

BACKGROUND: Crizotinib is the first tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC). An increased incidence of renal cysts has been described during the crizotinib treatment. CASE PRESENTATION: We herein report th...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Int Med Case Rep J
Egile Nagusiak: Di Marino, Pietro, Mannetta, Gianluca, Carella, Consiglia, Grassadonia, Antonino, Tinari, Nicola, Natoli, Clara, De Tursi, Michele
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove 2020
Gaiak:
Case Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7083626/
https://ncbi.nlm.nih.gov/pubmed/32214855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IMCRJ.S229080
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak